{"id":4034,"date":"2023-10-10T09:51:06","date_gmt":"2023-10-10T14:51:06","guid":{"rendered":"https:\/\/fifarma.org\/?p=4034"},"modified":"2024-05-17T12:11:55","modified_gmt":"2024-05-17T17:11:55","slug":"senales-contradictorias","status":"publish","type":"post","link":"https:\/\/fifarma.org\/en\/senales-contradictorias\/","title":{"rendered":"Se\u00f1ales contradictorias"},"content":{"rendered":"<p class=\"has-small-font-size\"><em>El Ministerio de Salud y Protecci\u00f3n Social de Colombia declar\u00f3, mediante la Resoluci\u00f3n 1579 de 2023, la existencia de razones de inter\u00e9s p\u00fablico para someter una patente del medicamento Dolutegravir a licencia obligatoria. \u00bfQu\u00e9 se\u00f1ales env\u00edan este tipo de decisiones a la industria de innovaci\u00f3n a nivel mundial?<\/em><\/p>\n\n\n\n<br><p class=\"has-small-font-size\"><strong><em>POR: YANETH GIHA<br>Directora Ejecutiva FIFARMA<\/em><\/strong><\/p><br>\n\n\n\n<p>La declaratoria de inter\u00e9s p\u00fablico es el paso previo para una licencia obligatoria, la cual es una medida leg\u00edtima con la que el Gobierno autoriza a terceros a fabricar, vender o importar un producto patentado, cuando se cumplen con unas circunstancias espec\u00edficas.&nbsp;<\/p>\n\n\n\n<p>En Colombia, el Ministerio de Salud est\u00e1 avanzando con esta medida para Dolutegravir, un tratamiento para el VIH, aunque las cifras no muestran que estamos en una situaci\u00f3n de extrema urgencia que amerite levantar la patente. Adicionalmente esta mol\u00e9cula no es la \u00fanica opci\u00f3n que existe para tratar a las personas diagnosticadas con VIH. En Colombia hay 19 medicamentos disponibles para esta enfermedad. Lo cual confirma que no hay barreras de acceso.<\/p>\n\n\n\n<p>Cuando se otorga una licencia obligatoria, sin que la situaci\u00f3n lo amerite, se pueden estar enviando se\u00f1ales contradictorias a la industria de innovaci\u00f3n.<\/p>\n\n\n\n<p>La primera se\u00f1al ser\u00eda incertidumbre y falta de estabilidad jur\u00eddica. Cabe anotar que, en la investigaci\u00f3n farmac\u00e9utica, la patente es el incentivo que se tiene para asumir los costos que implica el desarrollo de un medicamento innovador.<\/p>\n\n\n\n<p>Una segunda se\u00f1al es sembrar la idea de que en Colombia no se valoran los esfuerzos que se realizan en investigaci\u00f3n y desarrollo para productos innovadores. Y eso afecta no solo a la industria farmac\u00e9utica, sino que tambi\u00e9n genera desconfianza en otros sectores de innovaci\u00f3n como el software, las telecomunicaciones y las tecnolog\u00edas verdes, entre muchos m\u00e1s.<\/p>\n\n\n\n<p>Dos de los argumentos que se esgrimen en favor de las licencias obligatorias es que reducen precios y promueven la producci\u00f3n local. Pero hay casos documentados en donde eso no sucede. Hace un par de d\u00e9cadas en Zimbabue se emiti\u00f3 una licencia obligatoria para todos los medicamentos contra el VIH, pero el gen\u00e9rico lopinavir&nbsp;+&nbsp;ritonavir siempre ha sido m\u00e1s caro all\u00ed que el innovador original.<\/p>\n\n\n\n<p>Sobre el est\u00edmulo a la producci\u00f3n local, el ejemplo de un tratamiento antirretroviral de Brasil en 2007 es muy ilustrativo. El fabricante local tard\u00f3 dos a\u00f1os en comenzar la producci\u00f3n de una versi\u00f3n gen\u00e9rica. Y eso se explica porque la licencia obligatoria solo transfiere los derechos de patente; no los conocimientos t\u00e9cnicos, la capacidad, ni la calidad del producto.<\/p>\n\n\n\n<p>Las se\u00f1ales que env\u00edan este tipo de decisiones gubernamentales son contradictorias. Todos estamos de acuerdo en que la atenci\u00f3n de las personas con VIH es una prioridad y que, cada d\u00eda, debemos avanzar para que los pacientes de todas las enfermedades en Am\u00e9rica Latina tengan acceso a sus tratamientos, sin importar su capacidad econ\u00f3mica.<\/p>\n\n\n\n<p>Lo parad\u00f3jico de esta situaci\u00f3n es que, sin respeto por las patentes y la propiedad intelectual, jam\u00e1s se habr\u00eda podido desarrollar un tratamiento tan innovador como Dolutegravir. Actuar con visi\u00f3n cortoplacista puede terminar afectando, en el largo plazo, la salud de pacientes que requieren medicamentos de innovaci\u00f3n para tener una mejor expectativa y calidad de vida.<\/p>\n\n    <div class=\"xs_social_share_widget xs_share_url after_content \t\tmain_content  wslu-style-1 wslu-share-box-shaped wslu-fill-colored wslu-none wslu-share-horizontal wslu-theme-font-no wslu-main_content\">\n\n\t\t\n        <ul>\n\t\t\t        <\/ul>\n    <\/div>","protected":false},"excerpt":{"rendered":"<p>El Ministerio de Salud y Protecci\u00f3n Social de Colombia declar\u00f3, mediante la Resoluci\u00f3n 1579 de 2023, la existencia de razones de inter\u00e9s p\u00fablico para someter una patente del medicamento Dolutegravir a licencia obligatoria. \u00bfQu\u00e9 se\u00f1ales env\u00edan este tipo de decisiones a la industria de innovaci\u00f3n a nivel mundial? POR: YANETH GIHADirectora Ejecutiva FIFARMA La declaratoria [&hellip;]<\/p>","protected":false},"author":24,"featured_media":4042,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"enableOnePageScrollInPage":false,"onePageScrollCss":"","onePageScrollSpeed":1000,"onePageScrollAnimation":"easeInOutQuad","onePageScrollShowDotNavigation":true,"onePageScrollNavigation":"scaleUp","onePageScrollNavigationPosition":"right","onePageScrollNavigationHorizontal":[],"onePageScrollNavigationVertical":[],"onePageScrollNavigationSpacing":[],"onePageScrollNavigationColor":"#00ff0d","onePageScrollNavigationColorHover":"#00ff0d","onePageScrollNavigationColorActive":"#00ff0d","onePageScrollNavigationIcon":[],"onePageScrollNavigationWidth":[],"onePageScrollNavigationWidthHover":[],"onePageScrollNavigationWidthActive":[],"onePageScrollNavigationHeight":[],"onePageScrollNavigationHeightHover":[],"onePageScrollNavigationHeightActive":[],"onePageScrollNavigationBorder":[],"onePageScrollNavigationBorderHover":[],"onePageScrollNavigationBorderActive":[],"onePageScrollNavigationBorderRadius":[],"onePageScrollNavigationBorderRadiusHover":[],"onePageScrollNavigationBorderRadiusActive":[],"onePageScrollNavigationTooltipTypography":[],"onePageScrollNavigationTooltipColor":"#ffffff","onePageScrollNavigationTooltipColorHover":"","onePageScrollNavigationTooltipBgColor":"#00ff0d","onePageScrollNavigationTooltipBgColorHover":"","onePageScrollNavigationTooltipPadding":[],"onePageScrollNavigationTooltipPaddingHover":[],"onePageScrollNavigationTooltipBorderRadius":[],"onePageScrollNavigationTooltipBorderRadiusHover":[],"pageSettingsCustomCss":"","footnotes":""},"categories":[153,24,8,151],"tags":[98,69,71,68,73,72],"class_list":["post-4034","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-acceso","category-analisis","category-innovacion","category-propiedad-intelectual","tag-acceso","tag-colombia","tag-declaratoria-de-interes-publico","tag-ministerio-de-salud","tag-pacientes-con-vih","tag-tratamiento-vih-dolutegravir"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.7 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Se\u00f1ales contradictorias - FIFARMA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fifarma.org\/en\/senales-contradictorias\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Se\u00f1ales contradictorias\" \/>\n<meta property=\"og:description\" content=\"El Ministerio de Salud y Protecci\u00f3n Social de Colombia declar\u00f3, mediante la Resoluci\u00f3n 1579 de 2023, la existencia de razones de inter\u00e9s p\u00fablico para someter una patente del medicamento Dolutegravir a licencia obligatoria. \u00bfQu\u00e9 se\u00f1ales env\u00edan este tipo de decisiones a la industria de innovaci\u00f3n a nivel mundial? POR: YANETH GIHADirectora Ejecutiva FIFARMA La declaratoria [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fifarma.org\/en\/senales-contradictorias\/\" \/>\n<meta property=\"og:site_name\" content=\"FIFARMA\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-10T14:51:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-17T17:11:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fifarma.org\/wp-content\/uploads\/2023\/10\/YANETH-CASA-HOR.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1980\" \/>\n\t<meta property=\"og:image:height\" content=\"1320\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"fifarmacomunicaciones\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"fifarmacomunicaciones\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/senales-contradictorias\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/senales-contradictorias\\\/\"},\"author\":{\"name\":\"fifarmacomunicaciones\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/person\\\/f1731f7484686defa417316a8fe42068\"},\"headline\":\"Se\u00f1ales contradictorias\",\"datePublished\":\"2023-10-10T14:51:06+00:00\",\"dateModified\":\"2024-05-17T17:11:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/senales-contradictorias\\\/\"},\"wordCount\":572,\"publisher\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/senales-contradictorias\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/YANETH-CASA-HOR.png\",\"keywords\":[\"acceso\",\"Colombia\",\"Declaratoria de inter\u00e9s p\u00fablico\",\"Ministerio de Salud\",\"Pacientes con VIH\",\"Tratamiento VIH Dolutegravir\"],\"articleSection\":[\"Acceso\",\"An\u00e1lisis\",\"Innovaci\u00f3n\",\"Propiedad Intelectual\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/senales-contradictorias\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/senales-contradictorias\\\/\",\"name\":\"Se\u00f1ales contradictorias - FIFARMA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/senales-contradictorias\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/senales-contradictorias\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/YANETH-CASA-HOR.png\",\"datePublished\":\"2023-10-10T14:51:06+00:00\",\"dateModified\":\"2024-05-17T17:11:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/senales-contradictorias\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fifarma.org\\\/senales-contradictorias\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/senales-contradictorias\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/YANETH-CASA-HOR.png\",\"contentUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/YANETH-CASA-HOR.png\",\"width\":1980,\"height\":1320},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/senales-contradictorias\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/fifarma.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Se\u00f1ales contradictorias\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"name\":\"FIFARMA\",\"description\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"publisher\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fifarma.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\",\"name\":\"Fifarma\",\"alternateName\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"contentUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"width\":195,\"height\":39,\"caption\":\"Fifarma\"},\"image\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/person\\\/f1731f7484686defa417316a8fe42068\",\"name\":\"fifarmacomunicaciones\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g\",\"caption\":\"fifarmacomunicaciones\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Se\u00f1ales contradictorias - FIFARMA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fifarma.org\/en\/senales-contradictorias\/","og_locale":"en_US","og_type":"article","og_title":"Se\u00f1ales contradictorias","og_description":"El Ministerio de Salud y Protecci\u00f3n Social de Colombia declar\u00f3, mediante la Resoluci\u00f3n 1579 de 2023, la existencia de razones de inter\u00e9s p\u00fablico para someter una patente del medicamento Dolutegravir a licencia obligatoria. \u00bfQu\u00e9 se\u00f1ales env\u00edan este tipo de decisiones a la industria de innovaci\u00f3n a nivel mundial? POR: YANETH GIHADirectora Ejecutiva FIFARMA La declaratoria [&hellip;]","og_url":"https:\/\/fifarma.org\/en\/senales-contradictorias\/","og_site_name":"FIFARMA","article_published_time":"2023-10-10T14:51:06+00:00","article_modified_time":"2024-05-17T17:11:55+00:00","og_image":[{"width":1980,"height":1320,"url":"https:\/\/fifarma.org\/wp-content\/uploads\/2023\/10\/YANETH-CASA-HOR.png","type":"image\/png"}],"author":"fifarmacomunicaciones","twitter_card":"summary_large_image","twitter_misc":{"Written by":"fifarmacomunicaciones","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fifarma.org\/senales-contradictorias\/#article","isPartOf":{"@id":"https:\/\/fifarma.org\/senales-contradictorias\/"},"author":{"name":"fifarmacomunicaciones","@id":"https:\/\/fifarma.org\/#\/schema\/person\/f1731f7484686defa417316a8fe42068"},"headline":"Se\u00f1ales contradictorias","datePublished":"2023-10-10T14:51:06+00:00","dateModified":"2024-05-17T17:11:55+00:00","mainEntityOfPage":{"@id":"https:\/\/fifarma.org\/senales-contradictorias\/"},"wordCount":572,"publisher":{"@id":"https:\/\/fifarma.org\/#organization"},"image":{"@id":"https:\/\/fifarma.org\/senales-contradictorias\/#primaryimage"},"thumbnailUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2023\/10\/YANETH-CASA-HOR.png","keywords":["acceso","Colombia","Declaratoria de inter\u00e9s p\u00fablico","Ministerio de Salud","Pacientes con VIH","Tratamiento VIH Dolutegravir"],"articleSection":["Acceso","An\u00e1lisis","Innovaci\u00f3n","Propiedad Intelectual"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/fifarma.org\/senales-contradictorias\/","url":"https:\/\/fifarma.org\/senales-contradictorias\/","name":"Se\u00f1ales contradictorias - FIFARMA","isPartOf":{"@id":"https:\/\/fifarma.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fifarma.org\/senales-contradictorias\/#primaryimage"},"image":{"@id":"https:\/\/fifarma.org\/senales-contradictorias\/#primaryimage"},"thumbnailUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2023\/10\/YANETH-CASA-HOR.png","datePublished":"2023-10-10T14:51:06+00:00","dateModified":"2024-05-17T17:11:55+00:00","breadcrumb":{"@id":"https:\/\/fifarma.org\/senales-contradictorias\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fifarma.org\/senales-contradictorias\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fifarma.org\/senales-contradictorias\/#primaryimage","url":"https:\/\/fifarma.org\/wp-content\/uploads\/2023\/10\/YANETH-CASA-HOR.png","contentUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2023\/10\/YANETH-CASA-HOR.png","width":1980,"height":1320},{"@type":"BreadcrumbList","@id":"https:\/\/fifarma.org\/senales-contradictorias\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fifarma.org\/"},{"@type":"ListItem","position":2,"name":"Se\u00f1ales contradictorias"}]},{"@type":"WebSite","@id":"https:\/\/fifarma.org\/#website","url":"https:\/\/fifarma.org\/","name":"FIFARMA","description":"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica","publisher":{"@id":"https:\/\/fifarma.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fifarma.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fifarma.org\/#organization","name":"Fifarma","alternateName":"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica","url":"https:\/\/fifarma.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/","url":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","contentUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","width":195,"height":39,"caption":"Fifarma"},"image":{"@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/fifarma.org\/#\/schema\/person\/f1731f7484686defa417316a8fe42068","name":"fifarmacomunicaciones","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g","caption":"fifarmacomunicaciones"}}]}},"_links":{"self":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/posts\/4034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/comments?post=4034"}],"version-history":[{"count":0,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/posts\/4034\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/media\/4042"}],"wp:attachment":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/media?parent=4034"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/categories?post=4034"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/tags?post=4034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}